Anandamide, an endogenous cannabinoid, has a very low physical dependence potential

Journal of Pharmacology and Experimental Therapeutics

Volumn 287, Issue 2, 1998, Pages 598-605

  Aceto, Mario D ^a,c   Scates, Susan M ^a   Razdan, Raj K ^b   Martin, Billy R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ORGANIX INC   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANANDAMIDE; ARACHIDONIC ACID; CANNABINOID; RIMONABANT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DEPENDENCE; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; MALE; MASTICATION; NONHUMAN; PRIORITY JOURNAL; PTOSIS; RAT; SCRATCHING; WET DOG SHAKES;

ANIMALS; ARACHIDONIC ACID; ARACHIDONIC ACIDS; CANNABINOIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 0032468166     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Aceto MD (1990) Assessment of physical dependence techniques for the evaluation of abused drugs, in Modern Methods in Pharmacology: Testing and Evaluation of Drugs of Abuse (Adler MW and Cowan A eds) pp 76-79, Wiley-Liss, New York.
2. Aceto MD, Scates SM, Lowe JA and Martin BR (1995) Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. Eur J Pharmacol 282:R1-R2.
3. 9 tetrahydrocannabinol: Studies on precipitated and abrupt withdrawal. J Pharmacol Exp Ther 278:1290-1295.
4. Aceto MD, Tucker SM, Razdan RK and Martin BR (1994) Chronic exposure to anandamide, a purported cannabinoid: Long duration of action and development of physical dependence. Can J Physiol Pharmacol 72:Suppl. 1, 394 (Abstr.).
5. Adams IB, Compton D and Martin BR (1998) Assessment of anandamide interaction with the cannabinoid brain receptor SR 141716A: Antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther 284:1209-1217.
6. Adams IB, Ryan W, Singer M, Thomas BF, Compton BR, Razdan RK and Martin BR (1995) Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J Pharmacol Exp Ther 273:1172-1181.
7. Altman J, Everitt BJ, Glautier S, Markou A, Nutt D, Oretti R, Phillips GD and Robbins TW (1996) The biological, social and clinical bases of drug addiction: Commentary and debate. Psychopharmacology 125:285-345.
8. 9-tetrahydrocannabinol-induced responses and apparent agonist activily. J Pharmacol Exp Ther 277:586-594.
9. de Fonseca FR, Rocio M, Carrera A, Navarro M, Koob GF and Weiss F (1997) Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science (Wash DC) 276:2050-2054.
10. Devane WA and Axelrod J (1994) Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes. Proc Natl Acad Sci USA 91:6698-6701.
11. Devane WA, Dysarz FA, Johnson MR, Melvin LS and Howlett AC (1988) Determination and characterization of a cannabinoid receptorg in rat brain. Mol Pharmacol 34:605-613.
12. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A and Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949.
13. Deutsch DG and Chin SA (1993) Enzymatic synthesis of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 46:791-796.
14. Di Marzo V and De Petrocellis L (1997) The endogenous cannabinoid signaling system: Chemistry, biochemistry and physiology. Internet J Science Biol Chem 1:1-21.
15. Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K and Devane WA (1993) Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci USA 90:7656-7660.
16. Felder CC, Veluz JS, Williams HL, Briley EM and Matsuda LA (1992) Cannabinoid agonists stimulate both receptor- and nonreceptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol Pharmacol 42:838-845.
17. Fride E, Barg A and Levy R (1995) Low doses of anandamide inhibit pharmacological effects of delta-9-tetrahydrocannabinol. J Pharmacol Exp Ther 272:699-707.
18. Gaoni Y and Mechoulam R (1964) Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86:1646-1647.
19. Howlett AC, Johnson MR, Melvin LS and Milne GM (1988) Nonclassical cannabinoid analgetics inhibit adenylate cyclase: Development of a cannabinoid receptor model. Mol Pharmacol 33:297-302.
20. Jones RT and Benowitz N (1976) The 30-day trip - Clinical studies of cannabis tolerance and dependence, in Pharmacology of Marihuana (Bravde MC and Szara S eds) pp 627-642, Raven Press, New York.
21. Lichtman AH, Dimen KI and Martin BR (1995) Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology 119:282-290.
22. Martin BR, Compton DR, Little PJ, Martin TJ and Beardsley PM (1987) Structure-Activity Relationships of Cannabinoids. (Rapaka RS and Makriyannis A eds.) pp 108-122. NIDA Research Monograph Series, 79, US Government Printing Office, Washington, DC.
23. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC and Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (Lond) 346:561-564.
24. Mechoulam R, Fride E, Hanus L, Sheskin T, Bisogno T, Di Marzo V, Bayewitch M and Vogel Z (1997) Anandamide may mediate sleep induction. Nature (Lond) 389:25-26.
25. Mechoulam R and Fride E (1995) The unpaved road to the endogenous cannabinoid ligand anandamide, in Cannabinoids (Pertwee RG ed) pp 233-258, Academic Press, London.
26. 9 tetrahydrocannabinol and the cannabimimetic agents CP 55,940, WIN 55,212-2 and anandamide. Br J Pharmacol 110:1483-1490.
27. Pertwee RG (1991) Tolerance to and dependence on psychotropic cannabinoids, in The Biological Bases of Drug Tolerance and Dependence (Pratt J ed) pp 231-263, Academic Press, New York.
28. Richardson JD, Aanonson L and Hargreaves KM (1997) SR141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur J Pharmacol 319:R3-R4.
29. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D, Ferrara P, Soubrié P, Brelière JC and Le Fur G (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
30. Romero J, Garcia L, Ramos JA and Fernández-Ruiz JJ (1994) The putative receptor ligand, anandamide, stimulates hypothalamic tyrosine hydroxylase activity and inhibits prolactin release. Neuroendocrinol Lett 16:159-164.
31. Romero J, Garcia L, Cibeira M, Zadrozny D, Fernandez-Ruiz JJ and Ramos JA (1995) The endogenous cannabinoid receptor ligand, anandamide, inhibits motor behavior: Role of nigrostriatal dopaminergic neurons. Life Sci 56:2033-2040.
32. Schlicker E, Timm J and Gother M (1996) Cannabinoid receptor-mediated inhibition of dopamine release in the retina. Naunyn Schmiedeberg's Arch Pharmacol 354: 791-795.
33. Schuel H, Goldstein E, Mechoulam R, Zimmerman AM and Zimmerman S (1994) Anandamide (arachidoylethanolamide), a brain cannabinoid receptor agonist, reduces sperm fertilizing capacity in sea urchins by inhibiting the acrosome reaction. Proc Natl Acad Sci USA 91:7678-7682.
34. Schwarz H, Blanco FJ and Lotz M (1994) Anandamide, an endogenous cannabinoid receptor agonist, inhibits lymphocyte proliferation and induces apoptosis. J Neuroimmunol 55:107-115.
35. Teiger DG (1974) Induction of physical dependence on morphine, codeine, and meperidine in the rat by continuous infusion. J Pharmacol Exp Ther 190:408-415.
36. 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur J Pharmacol 280:R13-R15.
37. Weidenfeld J, Feldman S and Mechoulam R (1994) Effects of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinol 59:110-112.
38. 9-THC-induced interactions with dynorphinergic systems. Drug Alc Depend 45: 39-45.
39. Welch SP, Dunlow LD, Patrick GS and Razdan RK (1995) Characterization of anandamide and fluoroanandamide-induced antinociception and cross tolerance to delta-9-THC after intrathecal administration to mice: Blockade of delta-9-THC-induced antinociception. J Pharmacol Exp Ther 273:1235-1244.
40. 9-tetrahydrocannabinol in rats and rhesus monkeys. J Pharmacol Exp Ther 275:1-6.